Kura Oncology (KURA) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:47:59.866Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:47:59.866Z.

Quote observation: 2026-10-06T16:45:32.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -314,803,000
Quote market capitalization: 950,240,803
Total debt · period ending 2026-06-30: 24,455,000
Cash · period ending 2026-06-30: 70,242,000

FMP input reference: 19f1946388931e4ee5326c5171249fc23a65b0c9e42408d49e268755c1a57655

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

KURA EBITDA Yield Metrics

EBITDA YIELD

N/A

KURA Competitors' EBITDA Yield

KURA

Kura Oncology, Inc.

Current

Market Cap

$950.24M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLTX

MoonLake Immunotherapeutics

vs KURA

Market Cap

$938.31M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPTX

Seaport Therapeutics, Inc. Common Stock

vs KURA

Market Cap

$950.70M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBLL

CeriBell, Inc.

vs KURA

Market Cap

$931.87M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ODTX

Odyssey Therapeutics, Inc.

vs KURA

Market Cap

$924.12M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKTS

Aktis Oncology, Inc.

vs KURA

Market Cap

$980.51M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PCRX

Pacira BioSciences, Inc.

vs KURA

Market Cap

$983.98M

EBITDA Yield

8.70%

TTM Avg

9.22%

3Y Avg

7.66%

5Y Avg

6.32%

HSTM

HealthStream, Inc.

vs KURA

Market Cap

$916.63M

EBITDA Yield

7.95%

TTM Avg

9.57%

3Y Avg

8.00%

5Y Avg

7.50%

MGTX

MeiraGTx Holdings plc

vs KURA

Market Cap

$979.84M

EBITDA Yield

20.70%

TTM Avg

16.68%

3Y Avg

16.68%

5Y Avg

16.68%

PRCT

PROCEPT BioRobotics Corporation

vs KURA

Market Cap

$991.60M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Kura Oncology, Inc. (KURA)	$950.24M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$938.31M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$950.70M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$931.87M	N/A	N/A	N/A	N/A
Odyssey Therapeutics, Inc. (ODTX)vs ›	$924.12M	N/A	N/A	N/A	N/A
Aktis Oncology, Inc. (AKTS)vs ›	$980.51M	N/A	N/A	N/A	N/A
Pacira BioSciences, Inc. (PCRX)vs ›	$983.98M	8.70%	9.22%	7.66%	6.32%
HealthStream, Inc. (HSTM)vs ›	$916.63M	7.95%	9.57%	8.00%	7.50%
MeiraGTx Holdings plc (MGTX)vs ›	$979.84M	20.70%	16.68%	16.68%	16.68%
PROCEPT BioRobotics Corporation (PRCT)vs ›	$991.60M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

KURA EBITDA Yield Metrics

KURA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics